BACKGROUND: Approximately 20 % of patients diagnosed with colorectal cancer will have distant metastases at first presentation (stage IV disease). The effect of removing the primary tumor on survival for patients with stage IV disease with unresectable metastases remains unclear. To address this a meta-analysis of all studies comparing primary tumor resection with chemotherapy alone in cases of stage IV colorectal cancer with unresectable metastases was performed. METHODS: A comprehensive search for published studies examining the effect of primary tumor resection in the setting of colorectal cancer with unresectable metastases was performed. Each study was reviewed and data extracted. Random-effects methods were used to combine data. RESULTS: There were 21 studies including a total of 44,226 patients that met the inclusion criteria. Resection of the primary tumor in patients with unresectable metastases compared with chemotherapy alone was associated with a lower mortality risk (OR 0.28; 95 % CI 0.165-0.474; P < 0.001), translating into a difference in mean survival of 6.4 months in favor of resection (95 % CI 5.025-7.858, P < 0.001). Patients who underwent resection of the primary tumor were more likely to have liver metastasis only (OR 1.551; 95 % CI 1.247-1.929; P < 0.001), were less likely to have ≥2 metastasis (OR 0.653; 95 % CI 0.508-0.839; P = 0.001), and were less likely to have rectal cancer (OR 0.495; 95 % CI 0.390-0.629; P < 0.001). There was significant cross-study heterogeneity. CONCLUSIONS: Resection of the primary tumor may confer a survival advantage in stage IV colorectal cancer with unresectable metastases but significant selection bias exists in current studies. Randomized controlled trials are essential to validate these findings.
BACKGROUND: Approximately 20 % of patients diagnosed with colorectal cancer will have distant metastases at first presentation (stage IV disease). The effect of removing the primary tumor on survival for patients with stage IV disease with unresectable metastases remains unclear. To address this a meta-analysis of all studies comparing primary tumor resection with chemotherapy alone in cases of stage IV colorectal cancer with unresectable metastases was performed. METHODS: A comprehensive search for published studies examining the effect of primary tumor resection in the setting of colorectal cancer with unresectable metastases was performed. Each study was reviewed and data extracted. Random-effects methods were used to combine data. RESULTS: There were 21 studies including a total of 44,226 patients that met the inclusion criteria. Resection of the primary tumor in patients with unresectable metastases compared with chemotherapy alone was associated with a lower mortality risk (OR 0.28; 95 % CI 0.165-0.474; P < 0.001), translating into a difference in mean survival of 6.4 months in favor of resection (95 % CI 5.025-7.858, P < 0.001). Patients who underwent resection of the primary tumor were more likely to have liver metastasis only (OR 1.551; 95 % CI 1.247-1.929; P < 0.001), were less likely to have ≥2 metastasis (OR 0.653; 95 % CI 0.508-0.839; P = 0.001), and were less likely to have rectal cancer (OR 0.495; 95 % CI 0.390-0.629; P < 0.001). There was significant cross-study heterogeneity. CONCLUSIONS: Resection of the primary tumor may confer a survival advantage in stage IV colorectal cancer with unresectable metastases but significant selection bias exists in current studies. Randomized controlled trials are essential to validate these findings.
Authors: Ian S Reynolds; Aobhlinn O'Toole; Joseph Deasy; Deborah A McNamara; John P Burke Journal: Int J Colorectal Dis Date: 2017-01-11 Impact factor: 2.571
Authors: G Paul Wright; Katherine E Poruk; Mazen S Zenati; Jennifer Steve; Nathan Bahary; Melissa E Hogg; Amer H Zuriekat; Christopher L Wolfgang; Herbert J Zeh; Matthew J Weiss Journal: J Gastrointest Surg Date: 2016-09-07 Impact factor: 3.452
Authors: Zeinab Alawadi; Uma R Phatak; Chung-Yuan Hu; Christina E Bailey; Y Nancy You; Lillian S Kao; Nader N Massarweh; Barry W Feig; Miguel A Rodriguez-Bigas; John M Skibber; George J Chang Journal: Cancer Date: 2016-08-01 Impact factor: 6.860